Experimental drug may reduce lymphedema swelling and scarring
A clinical trial at Stanford Medicine has tested an experimental oral drug, acebilustat, as a potential treatment for lymphedema. The study suggests the drug may help reduce the chronic swelling and scarring associated with the condition, for which there are currently no approved medications.
Why it matters
This represents a potential breakthrough for patients suffering from a chronic, debilitating condition that currently relies on antiquated management techniques.
by Rachel Tompa, Stanford University Medical Center
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Unsplash Matthew Holbreich was a senior in college when the swelling started. He originally thought he had injured his left leg playing squash, but the intensity of the swelling scared him. After seeing a few doctors in Boston, where he was living at the time, he eventually was referred to Stanford Medicine's Stanley Rockson, M.D. A trip across the country resulted in a new diagnosis: lymphedema, a condition in which excess lymph fluid accumulates in a patient's arms or legs rather than draining through the lymphatic system into the bloodstream as it should.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in